NeuroVive Pharmaceutical AB Signs $7.6 Million JV With Isomerase Therapeutics
6/12/2013 7:21:22 AM
More...
|
NeuroVive Pharmaceutical AB: First Patient Recruited to Clinical Phase II Study for Treatment of Traumatic Brain Injury
6/5/2013 9:48:10 AM
More...
|
NeuroVive Pharmaceutical AB: European Phase III Study Approaches Its Final Stage
5/29/2013 9:59:06 AM
More...
|
NeuroVive Pharmaceutical AB: Interim Report 1 Jan. 2013 till 31 Mar. 2013
5/28/2013 8:28:17 AM
More...
|
NeuroVive Pharmaceutical AB Starts Investor Relations Partnership With Laika Consulting
5/8/2013 10:06:31 AM
More...
|
NeuroVive Pharmaceutical AB First Day of Trading on NASDAQ OMX Stockholm
4/10/2013 11:27:36 AM
More...
|
NeuroVive Pharmaceutical AB Admitted to Trading on NASDAQ OMX Stockholm
3/25/2013 9:44:38 AM
More...
|
NeuroVive Pharmaceutical AB Release: 600th Heart Attack Patient Recruited into Phase III CicloMulsion® CIRCUS Trial
3/22/2013 9:32:15 AM
More...
|
NeuroVive Pharmaceutical AB Appoints Anna Malm Bernsten and Boel Flodgren to Its Board of Directors
3/18/2013 9:49:11 AM
More...
|
Sihuan Pharmaceutical Holdings Group Ltd. Collaborates With NeuroVive Pharmaceutical AB to Develop Two Innovative Cardio-Cerebral Vascular Products in China
11/20/2012 9:02:07 AM
More...
|
|